Update on Nitrosamine Standards – NMBA Now Available

In the April 2019 publication of our newsletter “The Standard” we reported initial development of new native and isotopically labeled standards for N-nitroso-N-methyl-4-aminobutryic acid (NMBA), a potential human carcinogen that has received high interest lately as an impurity in certain ARB (angiotensin II receptor blocker) blood pressure and related medicines. We are happy to update that we have completed this synthesis, and these standards are now available along with our entire suite of nitrosamine standards.

Related Products

The Standard – October 2019